nemvaleukin alfa at architecture (C1); pathway selection, addressing differentiation skew
nemvaleukin alfa (il2 alpha bypass for treg avoidance) acts at the architecture (C1); pathway selection step of the cancer-immunity cycle. The failure mode is differentiation skew: factory output distribution shifts away from required mix. Wrong cell-type proportions, wrong product mix, wrong team configuration.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the architecture (C1); pathway selection step of the cancer-immunity cycle (factory regime, position P6), nemvaleukin alfa acts via il2 alpha bypass for treg avoidance. The failure mode is differentiation skew: factory output distribution shifts away from required mix. Wrong cell-type proportions, wrong product mix, wrong team configuration. The intervention's regime-type class lines up with the position's regime, and failure_differentiation_skew belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p6
- Failure modes
- failure_differentiation_skew
Evidence at generation
"nemvaleukin alfa" AND "cancer immunotherapy"
- PMID 34362793
Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys.
- PMID 37174716
Rethinking Oncologic Treatment Strategies with Interleukin-2.
Targets: —
nemvaleukin alfa cancer immunotherapy
- NCT04592653
Advanced Solid Tumor
Primary: Changes in density (cell counts per mm2) of immune cell (including total T cells, CD8+ T cells, CD56+ cells and Treg cells)
- NCT04830124
Cutaneous Melanoma
Primary: Centrally-assessed overall response rate (ORR) (Cohort 1 and 2)
- NCT04144517
Squamous Cell Carcinoma of Head and Neck
Primary: Overall Response Rate (ORR) Based on RECIST v1.1
- NCT02799095
Advanced Solid Tumors
Primary: Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)
- NCT03861793
Advanced Solid Tumors
Primary: Incidence of Adverse Events (AEs), and identify the RP2D of ALKS 4230 in Part A
Status timeline
- Draft2026-05-30T11:27:14Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system